Eddie Li to join Novo Nordisk as VP regulatory affairs

PRINCETON, N.J. — Novo Nordisk has appointed a new VP regulatory affairs.

Effective Sept. 12, Eddie Li will lead the drug maker's U.S. regulatory team and maintain relationships with individuals and agencies outside of Novo Nordisk that play a role in the Food and Drug Administration's review and approval process, the company said.

Li will report to Anne Philips, corporate VP clinical development, medical and regulatory affairs for North America.